Alliance Pharma’s (LON:APH) “Buy” Rating Reiterated at Numis Securities

Alliance Pharma (LON:APH)‘s stock had its “buy” rating reiterated by research analysts at Numis Securities in a research report issued to clients and investors on Monday, June 3rd, ThisIsMoney.Co.Uk reports.

LON:APH traded up GBX 1.10 ($0.01) during trading on Monday, reaching GBX 72.90 ($0.95). The company’s stock had a trading volume of 311,201 shares, compared to its average volume of 488,126. The company has a debt-to-equity ratio of 39.31, a quick ratio of 0.39 and a current ratio of 0.64. The company has a market capitalization of $378.89 million and a price-to-earnings ratio of 20.25. Alliance Pharma has a 12 month low of GBX 59.20 ($0.77) and a 12 month high of GBX 102 ($1.33). The company has a 50 day simple moving average of GBX 76.83.

Alliance Pharma Company Profile

Alliance Pharma plc operates as a specialty pharmaceutical company in the United Kingdom, rest of Europe, and internationally. The company acquires, markets, and sells pharmaceutical products. It acquires the rights of established products, and owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products.

See Also: Trading on Margin

Receive News & Ratings for Alliance Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply